Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (UH2/UH3)
The summary for the Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (UH2/UH3) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (UH2/UH3): The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize well-validated hit compounds through medicinal chemistry, or at the Development stage, to advance development candidates through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN participants receive intellectual property rights to drug candidates developed through the program.
Federal Grant Title: | Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (UH2/UH3) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Education Health Income Security and Social Services |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PAR-14-293 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.121, 93.213, 93.242, 93.273, 93.279, 93.853, 93.865, 93.866 |
CFDA Descriptions: | Oral Diseases and Disorders Research; Research and Training in Complementary and Alternative Medicine; Mental Health Research Grants; Alcohol Research Programs; Drug Abuse and Addiction Research Programs; Extramural Research Programs in the Neurosciences and Neurological Disorders; Child Health and Human Development Extramural Research; Aging Research |
Current Application Deadline: | May 7, 2017 |
Original Application Deadline: | May 7, 2017 |
Posted Date: | Jul 22, 2014 |
Creation Date: | Jul 22, 2014 |
Archive Date: | Jun 7, 2017 |
Total Program Funding: | |
Maximum Federal Grant Award: | none |
Minimum Federal Grant Award: | none |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- For profit organizations other than small businesses
Special district governments
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
City or township governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
County governments
Independent school districts
Public and State controlled institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
State governments
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Small businesses
Private institutions of higher education - Additional Information on Eligibility
- Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. - Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/pa-files/PAR-14-293.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
National Institutes of Health 301-496-3405 - Similar Government Grants
- • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...
- • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...
- • Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research ...
- • HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
- • NIDCR Mentoring Network to Promote a Diverse Dental, Oral and Craniofacial Research Workfo...
- • Epidemiological and Behavioral Research in Oral Health
- • Metagenomic Analyses of the Oral Microbiome
- • Phase Iii Clinical Trials in Oral Infectious Diseases
- More Grants from the National Institutes of Health
- • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...
- • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...
- • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)
- • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...
- • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...